A Phase 1 Single Ascending Dose Study of a Recombinant Hyperimmune Polyclonal Antibody Against SARS CoV-2 (GIGA-2050) in Patients Hospitalized With COVID-19
Latest Information Update: 28 Jan 2022
At a glance
- Drugs GIGA 2050 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors GigaGen
Most Recent Events
- 11 Jan 2022 Status changed from recruiting to discontinued.
- 11 Aug 2021 According to a GigaGen media release, the first patient has been dosed in this trial.
- 04 Jun 2021 Status changed from not yet recruiting to recruiting.